Brokerages Set Conatus Pharmaceuticals Inc (CNAT) PT at $12.62
Shares of Conatus Pharmaceuticals Inc (NASDAQ:CNAT) have received a consensus rating of “Buy” from the nine analysts that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $13.67.
Several equities research analysts recently commented on the company. S&P Equity Research increased their price target on Conatus Pharmaceuticals from $5.02 to $5.69 in a report on Wednesday, January 24th. Roth Capital assumed coverage on Conatus Pharmaceuticals in a report on Thursday. They issued a “buy” rating and a $20.00 price target for the company. Zacks Investment Research cut Conatus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, January 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $17.00 price target (down previously from $18.00) on shares of Conatus Pharmaceuticals in a report on Thursday, November 2nd.
Conatus Pharmaceuticals (NASDAQ:CNAT) traded up $0.03 during trading hours on Friday, hitting $5.07. The company had a trading volume of 1,175,880 shares, compared to its average volume of 407,267. Conatus Pharmaceuticals has a 12-month low of $3.88 and a 12-month high of $9.40. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.69 and a current ratio of 2.69. The firm has a market capitalization of $152.13, a PE ratio of -6.26 and a beta of 1.24.
A number of hedge funds have recently bought and sold shares of CNAT. Voya Investment Management LLC acquired a new stake in Conatus Pharmaceuticals during the second quarter worth $101,000. Wells Fargo & Company MN increased its stake in Conatus Pharmaceuticals by 3,098.0% during the third quarter. Wells Fargo & Company MN now owns 19,188 shares of the biotechnology company’s stock worth $105,000 after acquiring an additional 18,588 shares during the last quarter. New York State Common Retirement Fund increased its stake in Conatus Pharmaceuticals by 156.4% during the third quarter. New York State Common Retirement Fund now owns 24,100 shares of the biotechnology company’s stock worth $132,000 after acquiring an additional 14,700 shares during the last quarter. Rhumbline Advisers acquired a new stake in Conatus Pharmaceuticals during the second quarter worth $156,000. Finally, OxFORD Asset Management LLP acquired a new stake in Conatus Pharmaceuticals during the second quarter worth $230,000. 35.84% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This story was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.watchlistnews.com/brokerages-set-conatus-pharmaceuticals-inc-cnat-pt-at-12-62/1853392.html.
Conatus Pharmaceuticals Company Profile
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.